Invetx

Founded in 2018 and headquartered in Boston, Massachusetts, Invetx is a biopharmaceutical company building the world's premier animal health biotechnology platform. By leveraging validated protein-engineering technologies from human biopharma and optimizing them for veterinary application, Invetx develops novel, differentiated protein-based therapeutics to treat chronic and serious diseases in companion animals including dogs and cats. The company partners with leading biotech firms to generate best-in-class antibodies across a wide range of targets, aiming to transform standards of care in veterinary medicine. Invetx was acquired by Dechra Pharmaceuticals.